Diameride, tablets 1 mg 30 pcs

Diameride acts mainly by stimulating the secretion and release of insulin from the beta cells of the pancreas (pancreatic action). As with other sulfonylurea derivatives, this effect is based on increasing the response of pancreatic beta cells to physiological glucose stimulation, while the amount of insulin secreted is significantly lower than that of traditional drugs – sulfonylurea derivatives.

Indications

Type 2 diabetes mellitus when previously prescribed diet and exercise are ineffective.

Pharmacological effect

Diameride acts primarily by stimulating the secretion and release of insulin from the beta cells of the pancreas (pancreatic action). As with other sulfonylureas, this effect is based on an increase in the response of pancreatic beta cells to physiological stimulation by glucose, while the amount of insulin secreted is significantly less than with traditional sulfonylurea drugs.

Special instructions

Diameride should be taken in recommended doses and at the prescribed time. Errors in use of the drug, such as missing doses, should never be corrected by subsequent administration of a higher dose. The doctor and the patient should discuss in advance the measures that should be taken in case of such errors (for example, skipping a drug dose or meal) or in situations where it is impossible to take the next dose of the drug at the prescribed time.

Active ingredient

Glimepiride

Composition

1 tablet contains:

active substance:

glimepiride in terms of 100% substance – 1 mg.

excipients:

lactose monohydrate,

povidone,

poloxamer,

croscarmellose sodium,

microcrystalline cellulose,

magnesium stearate,

red iron oxide dye.

Contraindications

type 1 diabetes mellitus;
diabetic ketoacidosis, diabetic precoma and coma;
conditions accompanied by impaired absorption of food and the development of hypoglycemia (including infectious diseases);
leukopenia;
severe liver dysfunction;
severe renal impairment (including patients on hemodialysis);
hypersensitivity to glimepiride or to any inactive component of the drug, to other sulfonylurea derivatives or to sulfonamide drugs (risk of developing hypersensitivity reactions);
pregnancy and lactation;
lactose intolerance, lactase deficiency, glucose-galactose malabsorption;
children under 18 years of age.

With caution

Conditions requiring transfer of the patient to insulin therapy (extensive burns, severe multiple injuries, major surgical interventions, as well as impaired absorption of food and drugs in the gastrointestinal tract – intestinal obstruction, gastric paresis, etc.).

Side Effects

Metabolism: hypoglycemic reactions may develop. These reactions mainly occur soon after taking the drug, can be severe in form and course, and cannot always be easily controlled. The onset of these symptoms depends on individual factors, such as diet and dosage.

Interaction

The simultaneous use of glimepiride with certain drugs can cause either an increase or decrease in the hypoglycemic effect of the drug. Therefore, other medications can only be taken after consultation with your doctor.

Overdose

After ingestion of a large dose of glimepiride, hypoglycemia may develop, lasting from 12 to 72 hours, which may recur after the initial restoration of blood glucose concentrations. In most cases, observation in a hospital setting is recommended.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 ° C. Keep out of the reach of children.

Shelf life

2 years

Manufacturer

Akrikhin JSC, Russia